Helen Kent Chew
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Helen Kent Chew has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Gabriel N. Hortobagyi
The University of Texas MD Anderson Cancer Center, Houston, TX
3 shared publicationsA. M. Davies
Department of Internal Medicine, University of California Davis, Sacramento
2 shared publicationsDanika Lew
Southwest Oncology Group Statistical Center, Seattle, WA
2 shared publicationsDavid R. Gandara
University of California, Davis, Sacramento, CA
2 shared publicationsGeorge Somlo
City of Hope, Duarte, CA
2 shared publicationsJulie Gralow
Seattle Cancer Care Alliance, Seattle, WA
2 shared publications
Latest Publications
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (15_suppl) , 2549
Suppression of poly-ADP ribose (PAR) levels in PBMCs by veliparib (vel) as a pharmacodynamic (PD) marker associated with survival among women with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).
2549 Background: PARP inhibitor therapy of BRCA-associated cancer exploits the concept of synthetic lethality, yet there have been limited PD markers of efficacy. We report here on baseline PAR and suppression of PAR in PBMCs as a PD marker of clinical outcome, as well as pharmacokinetics (PK). Methods: Pts received either carboplatin (carb) IV and oral vel (Phase I) or single agent vel (Phase II) followed by post-progression therapy with the combination (NCI protocol #8264; NO1-CM-2011-00038). Blood for PK analysis (phase I only) and PBMCs were collected at baseline, at 3hrs, and at additional later time points. Plasma vel and PAR were quantitated using LC-MS assay and CTEP-validated reagents and methods, respectively. Results: 72 evaluable pts included 28 in Phase I, 44 in Phase II. PK samples were available for 25/28 pts in phase I; vel PK parameters are in line with values previously reported (Cl/F 20.9 L/h, V/F 173 L, t1/2 6.1 h). Response rate (RR) in phase I was 56% [CR rate 15%] and 3 remain in CR at 39, 42, and 46 months (2 on vel maintenance, 1 is off therapy). Paired baseline and 3 hr PBMC samples for PAR levels were available for 50 pts (18 phase I, 32 phase II). Higher baseline PAR levels (as a continuous variable) predict for better TTF (p < 0.01) and OS (p < 0.04), with marginal significance in PFS (p = 0.05) in Phase I patients. Using the median baseline PAR level from Phase I pts as a cut-point, there was increased hazard for the low PAR group (HR = 4.21 [1.39-12.8] in Phase I for TTF, and 2.1 [0.84-5.03] for Phase II). OS was worse for low PAR in both Phase I (HR = 2.75 [1.0-7.6]) and Phase II (HR = 3.7 [1.3-10.4]). Pts whose PAR level was reduced by more than 50% at 3 hrs also showed improved outcome. In multivariate analysis (including triple negativity, BRCA2 vs BRCA1, no. of sites, visceral disease, no. of prior Rx, ER/PR and age) only PAR (either the 50% reduction in PAR or baseline PAR < median, but not both as they were highly inversely correlated), was retained in the final prediction model for OS and TTF. Conclusions: Baseline level and reduction of PAR after treatment with vel associates with outcome among women with BRCA-associated MBC. Clinical trial information: NCT01149083.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (15_suppl) , 2549
Suppression of poly-ADP ribose (PAR) levels in PBMCs by veliparib (vel) as a pharmacodynamic (PD) marker associated with survival among women with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).
2549 Background: PARP inhibitor therapy of BRCA-associated cancer exploits the concept of synthetic lethality, yet there have been limited PD markers of efficacy. We report here on baseline PAR and suppression of PAR in PBMCs as a PD marker of clinical outcome, as well as pharmacokinetics (PK). Methods: Pts received either carboplatin (carb) IV and oral vel (Phase I) or single agent vel (Phase II) followed by post-progression therapy with the combination (NCI protocol #8264; NO1-CM-2011-00038). Blood for PK analysis (phase I only) and PBMCs were collected at baseline, at 3hrs, and at additional later time points. Plasma vel and PAR were quantitated using LC-MS assay and CTEP-validated reagents and methods, respectively. Results: 72 evaluable pts included 28 in Phase I, 44 in Phase II. PK samples were available for 25/28 pts in phase I; vel PK parameters are in line with values previously reported (Cl/F 20.9 L/h, V/F 173 L, t1/2 6.1 h). Response rate (RR) in phase I was 56% [CR rate 15%] and 3 remain in CR at 39, 42, and 46 months (2 on vel maintenance, 1 is off therapy). Paired baseline and 3 hr PBMC samples for PAR levels were available for 50 pts (18 phase I, 32 phase II). Higher baseline PAR levels (as a continuous variable) predict for better TTF (p < 0.01) and OS (p < 0.04), with marginal significance in PFS (p = 0.05) in Phase I patients. Using the median baseline PAR level from Phase I pts as a cut-point, there was increased hazard for the low PAR group (HR = 4.21 [1.39-12.8] in Phase I for TTF, and 2.1 [0.84-5.03] for Phase II). OS was worse for low PAR in both Phase I (HR = 2.75 [1.0-7.6]) and Phase II (HR = 3.7 [1.3-10.4]). Pts whose PAR level was reduced by more than 50% at 3 hrs also showed improved outcome. In multivariate analysis (including triple negativity, BRCA2 vs BRCA1, no. of sites, visceral disease, no. of prior Rx, ER/PR and age) only PAR (either the 50% reduction in PAR or baseline PAR < median, but not both as they were highly inversely correlated), was retained in the final prediction model for OS and TTF. Conclusions: Baseline level and reduction of PAR after treatment with vel associates with outcome among women with BRCA-associated MBC. Clinical trial information: NCT01149083.
- 20 June 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32  (18) , LBA9500
Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial.
LBA9500^ Background: Zoledronic acid (ZOL, 4 mg) every (q) 4 wk reduces the risk of skeletal-related events (SREs) in patients (pts) with bone metastases from breast cancer (BC). The OPTIMIZE-2 trial examined whether ZOL q12 wk was non-inferior to ZOL q4 wk in pts who had previously received monthly IV bisphosphonate (BP) therapy for ~1 year or longer. Methods: This was a prospective, randomized, double-blind, multicenter trial in female pts with bone metastases from BC who previously received ≥9 doses of IV BP (ZOL or pamidronate) during the first 10-15 months of therapy. Pts were randomized (1:1) to receive ZOL 4 mg IV q4 wk or q12 wk (placebo between ZOL doses to maintain blind) for 1 year. The primary endpoint was the proportion of pts with ≥1 SRE on study (SRE rate). Primary analysis was non-inferiority (pre-defined margin of 10%) for the difference in SRE rates. Secondary endpoints included time to first SRE, skeletal morbidity rate (SMR), bone pain score, change in bone turnover markers, and safety. Results: 403 pts were randomized to ZOL q4 wk (n = 200) or q12 wk (n = 203). Median age was 59 years, and baseline characteristics were similar between arms. The SRE rate was 22% and 23.2% in the ZOL q4 and q12 wk arms, respectively. The difference in SRE rate between arms was 1.2% (95% CI, –7.5% to 9.8%; P = .724). The upper limit of this 95% CI (9.8%) is less than the predefined margin of 10%, which indicates non-inferiority of ZOL q12 wk vs q4 wk. Times to first on-study SRE (HR, 1.06; 95% CI, 0.70 to 1.60; P = .792) were similar in the ZOL q4 and q12 wk arms, and mean SMRs were also similar (0.46 vs 0.50, respectively; P = .854). Overall, changes from baseline in bone turnover markers, and the incidence of treatment-emergent adverse events (TEAEs), were similar in the 2 arms. Numerically more renal TEAEs were reported in the ZOL q4 wk vs q12 wk arm (9.6% vs 7.9%, respectively). Two cases (1.0%) of osteonecrosis of the jaw (ONJ) were reported in the q4 wk arm. Conclusions: Among pts who had received monthly IV BP therapy for 1 year or longer, the efficacy of continuing ZOL for an additional year at q12 wk was non-inferior to ZOL q4 wk. Fewer renal AEs and none of the ONJ events were observed in the ZOL q12 wk vs ZOL q4 wk arm. Clinical trial information: NCT00320710.
- 20 June 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32  (18) , LBA9500
Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial.
LBA9500^ Background: Zoledronic acid (ZOL, 4 mg) every (q) 4 wk reduces the risk of skeletal-related events (SREs) in patients (pts) with bone metastases from breast cancer (BC). The OPTIMIZE-2 trial examined whether ZOL q12 wk was non-inferior to ZOL q4 wk in pts who had previously received monthly IV bisphosphonate (BP) therapy for ~1 year or longer. Methods: This was a prospective, randomized, double-blind, multicenter trial in female pts with bone metastases from BC who previously received ≥9 doses of IV BP (ZOL or pamidronate) during the first 10-15 months of therapy. Pts were randomized (1:1) to receive ZOL 4 mg IV q4 wk or q12 wk (placebo between ZOL doses to maintain blind) for 1 year. The primary endpoint was the proportion of pts with ≥1 SRE on study (SRE rate). Primary analysis was non-inferiority (pre-defined margin of 10%) for the difference in SRE rates. Secondary endpoints included time to first SRE, skeletal morbidity rate (SMR), bone pain score, change in bone turnover markers, and safety. Results: 403 pts were randomized to ZOL q4 wk (n = 200) or q12 wk (n = 203). Median age was 59 years, and baseline characteristics were similar between arms. The SRE rate was 22% and 23.2% in the ZOL q4 and q12 wk arms, respectively. The difference in SRE rate between arms was 1.2% (95% CI, –7.5% to 9.8%; P = .724). The upper limit of this 95% CI (9.8%) is less than the predefined margin of 10%, which indicates non-inferiority of ZOL q12 wk vs q4 wk. Times to first on-study SRE (HR, 1.06; 95% CI, 0.70 to 1.60; P = .792) were similar in the ZOL q4 and q12 wk arms, and mean SMRs were also similar (0.46 vs 0.50, respectively; P = .854). Overall, changes from baseline in bone turnover markers, and the incidence of treatment-emergent adverse events (TEAEs), were similar in the 2 arms. Numerically more renal TEAEs were reported in the ZOL q4 wk vs q12 wk arm (9.6% vs 7.9%, respectively). Two cases (1.0%) of osteonecrosis of the jaw (ONJ) were reported in the q4 wk arm. Conclusions: Among pts who had received monthly IV BP therapy for 1 year or longer, the efficacy of continuing ZOL for an additional year at q12 wk was non-inferior to ZOL q4 wk. Fewer renal AEs and none of the ONJ events were observed in the ZOL q12 wk vs ZOL q4 wk arm. Clinical trial information: NCT00320710.
- Open Access
- 22 February 2014
- Published by Springer Nature in SpringerPlus
- Vol. 3  (1) , 1-7
Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
- 22 February 2014
- Published by Springer Nature in SpringerPlus
- Vol. 3  (1) , 1-7
Open AccessPhase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
- 20 June 2013
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31  (18) , CRA1008
S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.
CRA1008 Background: S0221 is a SWOG-coordinated phase III adjuvant chemotherapy intergroup trial in node-positive and high-risk node-negative operable breast cancer which hypothesized that 1) the weekly AC+G regimen is superior to ddAC x 6 and 2) 12 weeks of weekly paclitaxel (wP) is superior to q 2 week paclitaxel x 6 (ddP). Methods: Between December 2003 and November 2010, 2,716 patients were randomized in a 2 x 2 factorial design to 1) AC+G vs ddAC and 2) P 80 mg/m2/week x 12 vs P 175 mg/m2 q 2 weeks x 6. If there was no significant interaction between the factors, the trial was powered to find a disease-free survival hazard ratio (HR) ≤ 0.82 for weekly vs q 2 week for each factor. At the first interim analysis, the AC randomization was halted for futility, and S0221 was closed to accrual 10 November 2010. S0221 reopened 15 December 2010, after which time all patients received 4 cycles of ddAC and randomization to P weekly x 12 and ddP x 6 continued. Accrual halted at a total of 3,294 in January 2012. Results: By September 7, 2012, 487 events and 340 deaths had occurred, prompting the third planned interim analysis. The Data Safety and Monitoring Committee recommended reporting the results since the futility boundary was crossed. A Cox model adjusting for the AC arms had a HR = 1.08 (95% CI 0.90-1.28; p=0.42), with the 99.5% CI excluding the original alternative hypothesis that the HR=0.82. There was no significant interaction of the two factors. Estimated 5-year progression-free survivals were 82% for weekly P and 81% for ddP. Toxicity data were available for 1,385 patients treated with ddP and 1,367 treated with weekly P. Grade 5 toxicity occurred in 4 patients on ddP and 2 on weekly P. Percent grade 3-4 toxicity per arm are shown in the Table. Conclusions: Either ddPx6 or weekly P x 12 are acceptable schedules of P administration. The differences in leukopenia likely reflect ascertainment bias against weekly P. If this is accepted, weekly P x 12 produces less overall toxicity than 6 cycles of ddP. Support: NCI grants CA32102, CA38926, CA21115, CA21076, CA77597, CA25224, CA77202, CCSRI15469, and Amgen, Inc. Clinical trial information: NCT00070564. [Table: see text]
- 20 June 2013
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31  (18) , CRA1008
S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.
CRA1008 Background: S0221 is a SWOG-coordinated phase III adjuvant chemotherapy intergroup trial in node-positive and high-risk node-negative operable breast cancer which hypothesized that 1) the weekly AC+G regimen is superior to ddAC x 6 and 2) 12 weeks of weekly paclitaxel (wP) is superior to q 2 week paclitaxel x 6 (ddP). Methods: Between December 2003 and November 2010, 2,716 patients were randomized in a 2 x 2 factorial design to 1) AC+G vs ddAC and 2) P 80 mg/m2/week x 12 vs P 175 mg/m2 q 2 weeks x 6. If there was no significant interaction between the factors, the trial was powered to find a disease-free survival hazard ratio (HR) ≤ 0.82 for weekly vs q 2 week for each factor. At the first interim analysis, the AC randomization was halted for futility, and S0221 was closed to accrual 10 November 2010. S0221 reopened 15 December 2010, after which time all patients received 4 cycles of ddAC and randomization to P weekly x 12 and ddP x 6 continued. Accrual halted at a total of 3,294 in January 2012. Results: By September 7, 2012, 487 events and 340 deaths had occurred, prompting the third planned interim analysis. The Data Safety and Monitoring Committee recommended reporting the results since the futility boundary was crossed. A Cox model adjusting for the AC arms had a HR = 1.08 (95% CI 0.90-1.28; p=0.42), with the 99.5% CI excluding the original alternative hypothesis that the HR=0.82. There was no significant interaction of the two factors. Estimated 5-year progression-free survivals were 82% for weekly P and 81% for ddP. Toxicity data were available for 1,385 patients treated with ddP and 1,367 treated with weekly P. Grade 5 toxicity occurred in 4 patients on ddP and 2 on weekly P. Percent grade 3-4 toxicity per arm are shown in the Table. Conclusions: Either ddPx6 or weekly P x 12 are acceptable schedules of P administration. The differences in leukopenia likely reflect ascertainment bias against weekly P. If this is accepted, weekly P x 12 produces less overall toxicity than 6 cycles of ddP. Support: NCI grants CA32102, CA38926, CA21115, CA21076, CA77597, CA25224, CA77202, CCSRI15469, and Amgen, Inc. Clinical trial information: NCT00070564. [Table: see text]
- Open Access
- 21 July 2011
- Published by Elsevier in Annals of Oncology
- Vol. 23  (4) , 1023-1029
Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors
Background: Chemotherapy in combination with small-molecule epidermal growth factor receptor inhibitors has yielded inconsistent results. Based on preclinical models, we conducted a phase I trial of two schedules of lapatinib and vinorelbine. Patient and methods: Patients had advanced solid tumors and up to two prior chemotherapeutic regimens. Patients were enrolled on two dose-escalating schedules of lapatinib, continuous (arm A) or intermittent (arm B), with vinorelbine on days 1, 8, and 15 of a 28-day cycle. Tumors from a subset of patients were evaluated for gene mutations and expression of targets of interest. Results: Fifty-one patients were treated. The most common grade 3/4 toxic effects included leukopenia, neutropenia, and fatigue. Dose-limiting toxic effects were grade 3 infection, febrile neutropenia, and diarrhea (arm A) and bone pain and fatigue (arm B). The maximum tolerated dose was vinorelbine 20 mg/m2 weekly and lapatinib 1500 mg daily (arm A) and vinorelbine 25 mg/m2 weekly and lapatinib 1500 mg intermittently (arm B). One patient on each arm had a complete response; both had human epidermal growth factor receptor 2-positive breast cancer. In a subset of patients, lack of tumor PTEN expression correlated with a shorter time to progression. Conclusion: In an unselected population, two schedules of lapatinib and vinorelbine were feasible and well tolerated.
- 21 July 2011
- Published by Elsevier in Annals of Oncology
- Vol. 23  (4) , 1023-1029
Open AccessPhase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors
Background: Chemotherapy in combination with small-molecule epidermal growth factor receptor inhibitors has yielded inconsistent results. Based on preclinical models, we conducted a phase I trial of two schedules of lapatinib and vinorelbine. Patient and methods: Patients had advanced solid tumors and up to two prior chemotherapeutic regimens. Patients were enrolled on two dose-escalating schedules of lapatinib, continuous (arm A) or intermittent (arm B), with vinorelbine on days 1, 8, and 15 of a 28-day cycle. Tumors from a subset of patients were evaluated for gene mutations and expression of targets of interest. Results: Fifty-one patients were treated. The most common grade 3/4 toxic effects included leukopenia, neutropenia, and fatigue. Dose-limiting toxic effects were grade 3 infection, febrile neutropenia, and diarrhea (arm A) and bone pain and fatigue (arm B). The maximum tolerated dose was vinorelbine 20 mg/m2 weekly and lapatinib 1500 mg daily (arm A) and vinorelbine 25 mg/m2 weekly and lapatinib 1500 mg intermittently (arm B). One patient on each arm had a complete response; both had human epidermal growth factor receptor 2-positive breast cancer. In a subset of patients, lack of tumor PTEN expression correlated with a shorter time to progression. Conclusion: In an unselected population, two schedules of lapatinib and vinorelbine were feasible and well tolerated.
- Open Access
- 11 May 2010
- Published by Portico in Clinical Medicine Reviews in Oncology
- Vol. 2  (2) , 177-188
Metastatic Breast Cancer: Focus on Capecitabine
Peer reviewed article authored by Mrinal Dutia and Helen K. Chew. Read full text article or submit your research paper for publishing.
- 11 May 2010
- Published by Portico in Clinical Medicine Reviews in Oncology
- Vol. 2  (2) , 177-188
Open AccessMetastatic Breast Cancer: Focus on Capecitabine
Peer reviewed article authored by Mrinal Dutia and Helen K. Chew. Read full text article or submit your research paper for publishing.
- 1 May 2009
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27  (13) , 2163-2169
Phase II Studies of Gemcitabine and Cisplatin in Heavily and Minimally Pretreated Metastatic Breast Cancer
Purpose: Cisplatin and gemcitabine have single-agent activity in metastatic breast cancer, and preclinical data support synergy of the combination. Two parallel, phase II trials were conducted to evaluate the response rate, response duration, and toxicities of the combination. Genetic polymorphisms were analyzed for correlation with outcomes. Patients and Methods: Eligible women had measurable disease and heavily or minimally pretreated metastatic breast cancer. The heavily pretreated protocol required prior anthracycline and taxane therapy; cisplatin as part of high-dose therapy was allowed. All patients received cisplatin 25 mg/m2 on days 1 through 4 and gemcitabine 1,000 mg/m2 on days 2 and 8 of a 21-day cycle with prophylactic granulocyte colony-stimulating factor in the heavily pretreated group. Sera from a subset of patients were evaluated by polymerase chain reaction restriction fragment length polymorphism for polymorphisms in 10 genes of interest. Results: Of 136 women enrolled, 74 were heavily pretreated. Both protocols accrued to their two-stage design. The response rate for both the heavily and minimally pretreated cohorts was 26%, and the median durations of response were 5.3 and 5.9 months, respectively. In a multivariate analysis, hormone receptor–negative disease was associated with a higher response rate. The most common grades 3 or 4 toxicities were thrombocytopenia (71%), neutropenia (66%), and anemia (38%). In a subset of 55 patients, the xeroderma pigmentosum group D (XPD)–751, x-ray cross-complementing group 3 (XRCC3) and cytidine deaminase polymorphisms were significantly associated with clinical outcomes. Conclusion: Combination cisplatin and gemcitabine is active in metastatic breast cancer regardless of prior therapy. Genetic polymorphisms may tailor which patients benefit from this regimen.
- 1 May 2009
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27  (13) , 2163-2169
Phase II Studies of Gemcitabine and Cisplatin in Heavily and Minimally Pretreated Metastatic Breast Cancer
Purpose: Cisplatin and gemcitabine have single-agent activity in metastatic breast cancer, and preclinical data support synergy of the combination. Two parallel, phase II trials were conducted to evaluate the response rate, response duration, and toxicities of the combination. Genetic polymorphisms were analyzed for correlation with outcomes. Patients and Methods: Eligible women had measurable disease and heavily or minimally pretreated metastatic breast cancer. The heavily pretreated protocol required prior anthracycline and taxane therapy; cisplatin as part of high-dose therapy was allowed. All patients received cisplatin 25 mg/m2 on days 1 through 4 and gemcitabine 1,000 mg/m2 on days 2 and 8 of a 21-day cycle with prophylactic granulocyte colony-stimulating factor in the heavily pretreated group. Sera from a subset of patients were evaluated by polymerase chain reaction restriction fragment length polymorphism for polymorphisms in 10 genes of interest. Results: Of 136 women enrolled, 74 were heavily pretreated. Both protocols accrued to their two-stage design. The response rate for both the heavily and minimally pretreated cohorts was 26%, and the median durations of response were 5.3 and 5.9 months, respectively. In a multivariate analysis, hormone receptor–negative disease was associated with a higher response rate. The most common grades 3 or 4 toxicities were thrombocytopenia (71%), neutropenia (66%), and anemia (38%). In a subset of 55 patients, the xeroderma pigmentosum group D (XPD)–751, x-ray cross-complementing group 3 (XRCC3) and cytidine deaminase polymorphisms were significantly associated with clinical outcomes. Conclusion: Combination cisplatin and gemcitabine is active in metastatic breast cancer regardless of prior therapy. Genetic polymorphisms may tailor which patients benefit from this regimen.
- 1 December 2008
- Published by Elsevier in Clinical Breast Cancer
- Vol. 8  (6) , 511-515
A Phase II Study of Imatinib Mesylate and Capecitabine in Metastatic Breast Cancer: Southwest Oncology Group Study 0338
- 1 December 2008
- Published by Elsevier in Clinical Breast Cancer
- Vol. 8  (6) , 511-515
A Phase II Study of Imatinib Mesylate and Capecitabine in Metastatic Breast Cancer: Southwest Oncology Group Study 0338
- 1 April 2008
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 6  (4) , 601-608
The incidence of venous thromboembolism among patients with primary lung cancer
- 1 April 2008
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 6  (4) , 601-608
The incidence of venous thromboembolism among patients with primary lung cancer
- 1 February 2008
- Vol. 11  (2) , 90-3
25th Chemotherapy Foundation Symposium. Innovative Cancer Therapy for Tomorrow. 6-10 November 2007, New York, NY, USA.
- 1 February 2008
- Vol. 11  (2) , 90-3
25th Chemotherapy Foundation Symposium. Innovative Cancer Therapy for Tomorrow. 6-10 November 2007, New York, NY, USA.